



## Epichem successful in WA business support program for advanced technologies

**29 March 2021 – Perth, Australia:** PharmAust Limited (ASX:PAA), a clinical-stage oncology company, is pleased to announce that its wholly owned subsidiary Epichem Pty Ltd has been accepted into the Quantum Technology Exchange (QTX WA) Cross Sector Acceleration Program.

The program will support Epichem's development of its Oxidative Hydrothermal Dissolution (OHD) technology to convert feedstock and biomass into useful end products, recover valuable metals and produce useful high value chemicals.

Epichem will meet speakers and coaches from a range of areas, including key representatives from companies such as Woodside Energy, BHP, Roy Hill, Rio Tinto, AROSE, Fugro SpAARC, Robotics Australia Group, InmarSAT, The Australian Space Agency, NOVA Systems, METS Ignited, SmartSAT CRC, NERA, Telstra, Austmine, CISCO, Defence West and Thales New Energy.

Epichem will benefit from mentoring, facilitated market engagement, profile raising, staff development, multi sector opportunities and expand its networks from this program.

Epichem's CEO Mr Colin La Galia said, "We are pleased to get this extra support. It will help us with the scale up of our OHD project and other Epichem projects."

The program is co-sponsored by the National Energy Resources Australia (NERA) and Atomic Sky. It is offered for scale-up solutions and business acceleration in the mining, energy, agriculture, defence and space industries, in digital technologies, automation and remote operations, data sciences, sustainability and clean energy.

This announcement is authorised by the Board.

### Enquiries:

**Mr Colin La Galia**  
CEO Epichem  
Tel: 08 6167 520  
[colin.lagaliam@epichem.com.au](mailto:colin.lagaliam@epichem.com.au)

**Dr Roger Aston**  
Executive Chairman  
Tel: 0402 762 204  
[rogeraston@pharmaust.com](mailto:rogeraston@pharmaust.com)

### About Epichem:

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in over 40 countries worldwide for over 17 years. Epichem has newly constructed purpose-built, state-of-the-art laboratories and has world class equipment and expertise in synthetic and medicinal chemistry to support drug discovery projects, and for the cost-effective synthesis of drug analogue libraries and intermediates. It also has a rapidly growing catalogue of pharmaceutical reference standards. Epichem is the winner of the WA Industry Export Award 2019 for International Health, the 2020 Inspiring Story of Celebrating Remarkable Resilience Nomination for WA for the Australian Export and Investment Awards and the 2020 GHP Biotechnology Award winner for Most Innovative Chemistry Service Provider – Australia and Best in Organic Chemistry Solutions 2020. Epichem generated Aus\$3.5M in revenues in the 2020 FY.

For more information, visit [www.epichem.com.au](http://www.epichem.com.au)

**About PharmAust (PAA):**

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials

**About Atomic Sky:**

Atomic Sky is a leader delivering impact through purpose-led strategic innovation. Delivering exceptional depth in major technology trends impacting world transformation initiatives and digital change.

The Atomic Agile Innovation Process has helped design, develop and deliver success for sectors, large corporations, government and growth companies.

Focused on results and outcomes against strategic intent, they help tackle large problems, create competitive advantage and build sustainable culture change through action, working with teams on strategy, programs and or execution, creating collaboration, incubation and impact internally and externally.

**About NERA:**

NERA is Australia's Industry Growth Centre for the energy resources sector, uniquely positioned to support sector-wide transformation and unlock +\$10 billion of new value for the Australian economy.

NERA is an industry broker and the source of insight into challenges, solutions, skills and regulation that will ensure Australia maximises its huge energy resources advantage and becomes a global energy powerhouse.

Since its inception in 2016, NERA has worked to maximise the value to the Australian economy by developing an energy resources sector that is globally competitive, sustainable, innovative and diverse.

NERA is engaged across the value chain to achieve significant industry efficiencies; identify and support digital, automation and other innovative technologies; develop future workforce skills; and ensure that there are regulatory frameworks that support future investment, innovation, productivity and global trade.